Company research
20/20 Biolabs, Inc.
CIK 1139685Updated Sep 27, 2026
SecurityAIDX · NASDAQ · equity
Name history
20/20 GeneSystems, Inc. · through Feb 26, 202520/20 GENE SYSTEMS INC · through Apr 28, 2004
AIDX price & chart
Loading TradingView…
NASDAQ:AIDX on TradingView ↗About the company
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper-arm capillary collection devices that avoid painful needles. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Regulation FD Disclosure
Items 7.01, 9.01
DEFA14A filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
424B3 filing
424B3 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 4,137,357Source | 3,584,408Source |
| Property, Plant and Equipment, NetUSD | 56,677Source | 116,669Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 202,264Source | 205,529Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,025,987Source | 1,784,009Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 199,954Source | 135,272Source |
| Inventory, NetUSD | 116,217Source | 47,164Source |
| Assets, CurrentUSD | 1,471,133Source | 2,034,225Source |
| Prepaid Expense and Other Assets, CurrentUSD | 128,975Source | 67,780Source |
| Operating Lease, Right-of-Use AssetUSD | 605,289Source | 772,385Source |
| Other Assets, NoncurrentUSD | 23,057Source | 161,957Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 4,156,582Source | 2,078,926Source |
| Stockholders’ equity: | ||
| Common Stock, Value, IssuedUSD | 54,422Source | 48,231Source |
| Additional Paid in CapitalUSD | 33,126,398Source | 30,947,601Source |
| Retained Earnings (Accumulated Deficit)USD | -33,247,219Source | -29,508,398Source |
| Stockholders' Equity Attributable to ParentUSD | -19,225Source | 1,505,482Source |
| Liabilities and EquityUSD | 4,137,357Source | 3,584,408Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 2,463,141Source | 1,355,078Source |
| Operating Lease, Liability, CurrentUSD | 175,948Source | 165,702Source |
| Accounts Payable, CurrentUSD | 868,545Source | 372,303Source |
| Operating Lease, Liability, NoncurrentUSD | 488,725Source | 673,848Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 785,784Source | 346,622Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, Depletion and AmortizationUSD | 63,257Source | 116,035Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 516,180Source | 2,176,098Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts ReceivableUSD | 64,682Source | 66,438Source |
| Increase (Decrease) in InventoriesUSD | 69,052Source | -13,504Source |
| Increase (Decrease) in Accounts PayableUSD | 496,242Source | 12,025Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -1,919,720Source | -2,598,785Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,161,698Source | 293,333Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -758,022Source | -2,305,452Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,025,987Source | 1,784,009Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 516,180Source | 2,176,098Source |
| Amortization of Intangible AssetsUSD | 22,500Source | 22,500Source |
| DepreciationUSD | 59,992Source | 111,178Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 7,737Source | — |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | -16,356Source |
| Gain (Loss) on Extinguishment of DebtUSD | -280,764Source | — |
| InterestExpenseNonoperatingUSD | 156,207Source | 12,646Source |
| Investment Income, InterestUSD | 21,399Source | 79,467Source |
| Net Income (Loss) Attributable to ParentUSD | -3,738,821Source | -5,551,667Source |
| Nonoperating Income (Expense)USD | -407,950Source | 125,746Source |
| Operating ExpensesUSD | 3,935,412Source | 6,037,724Source |
| Other Nonoperating Income (Expense)USD | -115Source | 58,925Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 2,045,133Source | 1,752,343Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 2,045,133Source | 1,752,343Source |
| Cost of Goods and Services Sold | — | — |
| Selling, General and Administrative ExpenseUSD | 3,342,843Source | 4,759,587Source |
| Operating Income (Loss)USD | -3,330,871Source | -5,677,413Source |
| Other Nonoperating Income (Expense)USD | -115Source | 58,925Source |
| Net Income (Loss) Attributable to ParentUSD | -3,738,821Source | -5,551,667Source |
| Earnings Per Share, BasicUSD per share | -0.76Source | -1.16Source |
| Earnings Per Share, DilutedUSD per share | -0.76Source | -1.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,930,287Source | 4,800,524Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,930,287Source | 4,800,524Source |
| Interest Expense (non-operating)USD | 156,207Source | 12,646Source |
| Additional Financial Items | ||
| Amortization of Intangible AssetsUSD | 22,500Source | 22,500Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 7,737Source | — |
| Gross ProfitUSD | 604,541Source | 360,311Source |
| Investment Income, InterestUSD | 21,399Source | 79,467Source |
| Nonoperating Income (Expense)USD | -407,950Source | 125,746Source |
| Operating ExpensesUSD | 3,935,412Source | 6,037,724Source |
| Research and Development ExpenseUSD | 592,569Source | 1,261,781Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 2,045,133Source | 1,752,343Source |
Offerings
Registration 333-294903
Registration 333-292125
Filing attachments
ea030445501ex99-1.htm · 8-K · 2026-09-02
EX-99.1 2 ea030445501ex99-1.htm INVESTOR PRESENTATION, SEPTEMBER 2026 Exhibit 99.1 Investor Webinar NASDAQ: AIDX September 2, 2026 Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information currently available and are subject to risks and uncertainties t…
Read attachment ↗ea030215301ex99-1.htm · 8-K · 2026-08-17
EX-99.1 2 ea030215301ex99-1.htm PRESS RELEASE ISSUED ON AUGUST 17, 2026 Exhibit 99.1 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level Total Revenue Increased 37% to $0.7 Million and Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5% Best Quarter of Multi-Cancer Early Detection Testing, with OneTest™ Revenue Up 47% Year-Over-Year to $0.7 Million Cash P…
Read attachment ↗ea030072601ex99-1.htm · 8-K · 2026-08-05
EX-99.1 2 ea030072601ex99-1.htm INVESTOR PRESENTATION, AUGUST 2026 Exhibit 99.1 NASDAQ: AIDX Investor Webinar August 5, 2026 Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information currently available and are subject to risks and uncertainties that co…
Read attachment ↗ea029673601ex99-1.htm · 8-K · 2026-07-01
EX-99.1 2 ea029673601ex99-1.htm INVESTOR PRESENTATION, JULY 2026 Exhibit 99.1 NASDAQ: AIDX Investor Webinar July 1, 2026 Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information currently available and are subject to risks and uncertainties that could …
Read attachment ↗ea029164201ex99-1.htm · 8-K · 2026-05-20
EX-99.1 2 ea029164201ex99-1.htm PRESS RELEASE ISSUED ON MAY 20, 2026 Exhibit 99.1 20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Co…
Read attachment ↗ea028793301ex4-4.htm · 8-K · 2026-04-28
EX-4.4 2 ea028793301ex4-4.htm GLOBAL AMENDMENT, DATED APRIL 23, 2026, BETWEEN STREETERVILLE CAPITAL, LLC AND 20/20 BIOLABS, INC Exhibit 4.4 GLOBAL AMENDMENT This Global Amendment (this “Amendment”) is entered into as of April 23, 2026 (the “Effective Date”), by and between Streeterville Capital, Llc, a Utah limited liability company (“Investor”), and 20/20 Biolabs, Inc., a Delaware corporation (“Company”). A. Company previously sold and issued to Investor that certain: (i) Warrant No. 1 t…
Read attachment ↗